Psychedelics Majority of Americans support regulating psychedelics: UC Berkeley survey The survey results follow the city of Berkeley decriminalizing psychedelic plants and fungi on Tuesday Rowan DunneJuly 13, 2023
Psychedelics Stella acquires Field Trip’s U.S. assets to enhance its psychedelic therapy offerings Stella closed a US$7 million funding round led by Sterling Partners last month Rowan DunneJune 28, 2023
Psychedelics Numinus partners with HealingMaps to promote its clinics and identify expansion targets HealingMaps was created to provide people with info about psychedelic therapy and help them find clinics Rowan DunneJune 22, 2023
News Optimi Health completes harvesting psilocybin mushrooms for Australia-bound medical extract Australia will allow psychiatrists to prescribe psilocybin and MDMA for certain conditions as of July 1 Natalia Buendia CalvilloMay 17, 2023
Psychedelics EntheoTech Bioscience opens flagship ketamine clinic in Kelowna The company has established a 3,000-square-foot facility to help cater to the growing demand for ketamine therapy Rowan DunneMay 5, 2023
News Numinus Wellness YoY revenue increased five times to $5.4M Numinus clinic network generated $4.7 million in revenue during Q2 2023, showing a significant increase of 596.9 per cent from the same period last... Natalia Buendia CalvilloApril 13, 2023
News Psilocybin decreases depression in cancer patients: study Depression impacts 1 in 4 people with cancer and often becomes a debilitating aspect of their diagnosis Natalia Buendia CalvilloApril 13, 2023
Psychedelics MGC Pharma gets permission from Slovenian health authorities to research psilocybin MGC says it is the first company operating in Slovenia to obtain permission to engage in studies on the psychedelic compound Rowan DunneApril 5, 2023
Psychedelics Optimi Health submits clinical trial application after developing proprietary MDMA drug The drug will be used to help establish a safe supply for patients in Canada and Australia Rowan DunneFebruary 7, 2023
Psychedelics Awakn set to research ketamine for alcohol use disorder The trial will be held at 7 NHS sites in the U.K. with the NIHR funding 66% of the cost Rowan DunneDecember 14, 2022